The DIAN study

Brain and Nerve

Volumn 65, Issue 10, 2013, Pages 1179-1184

  Shimada, Hiroyuki ^a  

^a OSAKA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

A4; Alzheimer's disease; API; DIAN

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; BETA SECRETASE INHIBITOR; BIOLOGICAL MARKER; MONOCLONAL ANTIBODY; SOLANEZUMAB; TAU PROTEIN;

ALZHEIMER DISEASE; CEREBROSPINAL FLUID; COGNITION; GENE MUTATION; HIPPOCAMPUS; HUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; BIOLOGICAL MARKERS; HUMANS; MUTATION; PEPTIDE FRAGMENTS; SEX CHARACTERISTICS;

EID: 84886731238     PISSN: 18816096     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Klunk WE, Engler H, Nordberg A, Wang Y, Blomqvist G, et al: Imaging brain amyloid in Alzheimer's disease with Pittsburgh compound-b. Ann Neurol 55: 306-319, 2004
2. Bateman RJ, Xiong C, Benzinger TL, Fagan AM, Goate A, et al: Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med 367: 795-804, 2012
3. Hardy J, Selkoe DJ: The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 297: 353-356, 2002
4. Braak H, Braak E: Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 18: 351-357, 1997
5. Jack CR Jr, Knopman DS, Jagust WJ, Shaw LM, Aisen PS, et al: Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9: 119-128, 2010
6. Price JL, Morris JC: Tangles and plaques in non-demented aging and "preclinical" Alzheimer's disease. Ann Neurol 45: 358-368, 1999
7. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, et al: The Alzheimer's disease neuroimaging initiative: a review of papers published since its inception. Alzheimers Dement 8: S1-S68, 2012
8. Perrin RJ, Fagan AM, Holtzman DM: Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 461: 916-922, 2009
9. Cruchaga C, Haller G, Chakraverty S, Mayo K, Vallania FL, et al: Rare variants in APP, PSEN1 and PSEN2 increase risk for ad in late-onset alzheimer's disease families. PloS ONE 7: e31039, 2012
10. Lopera F, Ardilla A, Martinez A, Madrigal L, Arango-Viana JC, et al: Clinical features of early-onset Alzheimer disease in a large kindred with an e280a presenilin-1 mutation. JAMA 277: 793-799, 1997
11. Wijsman EM, Daw EW, Yu X, Steinbart EJ, Nochlin D, et al: Apoe and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet 132B: 14-20, 2005
12. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, et al: Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292, 2011
13. Ewers M, Insel P, Jagust WJ, Shaw L, Trojanowski JJ, et al; Alzheimer's Disease Neuroimaging Initiative (ADNI): CSF biomarker and PIB-PET-derived beta-amyloid signature predicts metabolic, gray matter, and cognitive changes in nondemented subjects. Cereb Cortex 22: 1993-2004, 2012
14. Morris JC, Roe CM, Xiong C, Fagan AM, Goate AM, et al: ApoE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol 67: 122-131, 2010
15. Storandt M, Head D, Fagan AM, Holtzman DM, Morris JC: Toward a multifactorial model of Alzheimer disease. Neurobiol Aging 33: 2262-2271, 2012
16. Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, et al: Accelerated cortical atrophy in cognitively normal elderly with high beta-amyloid deposition. Neurology 78: 477-484, 2012
17. Pike KE, Ellis KA, Villemagne VL, Good N, Chetelat G, et al: Cognition and beta-amyloid in preclinical Alzheimer's disease: data from the AIBL study. Neuropsychologia 49: 2384-2390, 2011
18. Kantarci K, Lowe V, Przybelski SA, Weigand SD, Senjem ML, et al: ApoE modifies the association between A-beta load and cognition in cognitively normal older adults. Neurology 78: 232-240, 2012
19. Acosta-Baena N, Sepulveda-Falla D, Lopera-Gomez CM, Jaramillo-Elorza MC, Moreno S, et al: Predementia clinical stages in presenilin 1 E280A familial early-onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol 10: 213-220, 2011
20. Reiman EM, Quiroz YT, Fleisher AS, Chen K, Velez-Pardo C, et al: Brain imaging and fluid biomarker analysis in young adults at genetic risk for autosomal dominant Alzheimer's disease in the presenilin 1 e280a kindred: a case-control study. Lancet Neurol 11: 1048-1056, 2012
21. Fleisher AS, Chen K, Quiroz YT, Jakimovich LJ, Gomez MG, et al: Florbetapir pet analysis of amyloid-beta deposition in the presenilin 1 e280a autosomal dominant Alzheimer's disease kindred: a crosssectional study. Lancet Neurol 11: 1057-1065, 2012
22. Villemagne VL, Pike KE, Chetelat G, Ellis KA, Mulligan RS, et al: Longitudinal assessment of A-beta and cognition in aging and Alzheimer disease. Ann Neurol 69: 181-192, 2011